Elaina M. Gartner

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 598 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang et al. · Journal of Clinical Oncology · 2020 · 311 citations · Full text

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

Robert H. Vonderheide, Patricia LoRusso, Magi Khalil et al. · Clinical Cancer Research · 2010 · 301 citations

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Nizar M. Tannir, Andres Forero‐Torres, Radhakrishnan Ramchandren et al. · Investigational New Drugs · 2014 · 126 citations

Lymphoid Neoplasia, Urology, Genitourinary Cancer +5